With jockeys and their racehorses out of the gates to make up for the losses during H120, a resurge of COVID cases muddied the track again, slowing the finish to the 2020 Derby.

If the US Orthobio Market was off racing again in Q320, the racetrack got a bit muddy with a resurgence of positive COVID-19 cases, which halted or placed restrictions on elective procedures in some US states. Spine procedure volumes were particularly affected by the renewed restrictions in Q420, which had a domino effect of negatively impacting the Bone Replacement segment for Q4 and FY20, respectively.

Among the many topics covered in the comprehensive Q420/FY20 US Orthobio Market Recap* are:

As the Covid-19 pandemic continues its unprecedented impact on economies around the world, the MedTech industry presses on with product innovation and plans for the future. SmartTRAK reports daily on the challenges still ahead, covering all aspects of the OrthoBio market.

The following is just a small sampling of recent OrthoBio updates from around the world compiled, reviewed and posted in real time by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, patents, trends, new products, financial data and competitor developments in the global Life Sciences industry.

As part of SmartTRAK's R&D appreciation month, Research & Development professionals can now sign up for a Complimentary Month of Daily Updates delivered straight to your inbox. Just let us show you SmartTRAK and we'll give you a month of Daily Updates, delivered to your inbox, for FREE!

Dr. Wasik Ashraf, an Orthopaedic Surgeon specializing in Sports Medicine, discusses trends and innovation in Orthobiologics and Regenerative Medicine in an interview with SmartTRAK.

In this wide-ranging interview, Dr. Ashraf gives his view of CMS' FY21 OPPS-ASC Final Rulemaking, and discusses emerging trends and innovation in OrthoBiologics and Regenerative Medicine. As a Board-certified and fellowship-trained physician specializing in sports medicine, joint preservation and cartilage restoration, Dr. Ashraf offers his unique view and perspective on some of the newest technologies he is using, as well as those to look out for in the coming years. 

To listen to the interview, recorded live via Uberconference, click on the following video (41:37 min). A transcript of the interview is also available below.

The US market for Hemostats and Sealants continued back toward its pre-pandemic levels, gaining +20.0% QoQ and up +1.1% YoY. For FY20, the market declined, as COVID-19 delayed procedures in Q220 proved too much to overcome.

As the US Healthcare system learned to navigate the new normal and elective procedures continued their return toward COVID-19 levels, the US Hemostats and Sealants market finally exceeded pre-pandemic levels, up +1.1% YoY according to SmartTRAK Financial Dashboard. However, for the year the market was down as Q220’s delayed procedures proved too much to overcome.

Among the many topics covered in the comprehensive Q420/FY20 US Hemostats and Sealants Market Recap* are:

Q320 - The bright ray of sunshine companies had hoped for after dismal results in Q220

While Q220 is down in history as a disastrous quarter, marred by the dark mark of COVID-19, Q320 is the bright ray of sunshine companies in the US Joint Fluid Replacement market had hoped for.

For Q320, HA companies shared upbeat notes about renewed product demand, fueled by an uptick in activity from patients (out and about), distribution channels, and physicians treating an influx of new, as well as existing patients. One of the factors benefiting the HA market is the backlog of patients awaiting their turn for knee arthroplasty (TKA) and remain in need of treatment to manage their knee osteoarthritis (KOA) pain. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 US Joint Fluid Market Recap* are:

Orthopedics market stages a third-quarter rally while navigating a new norm.

As the US healthcare system adjusts to the “new” norm brought on by the COVID-19 pandemic, the US Orthobiologics market rallied in Q320, ending the quarter up +2.3% YoY. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Orthobio Market Recap* are:

During the month of October, the International Cartilage Regeneration & Joint Preservation Society (ICRS) hosted its first virtual convention, allowing stakeholders to come together to learn about the latest cartilage repair techniques, review recent clinical outcomes and explore new products via a virtual hall.

The Regenerative Medicine market for orthopedic and sports medicine applications is rapidly advancing as clinicians increasingly look to novel injectable options to accelerate the healing of injured joints, tendons and/or other soft tissues. Several companies are conducting research into the use of PRP, BMA/BMC, amniotic tissue products, exosomes and other regenerative medicine therapies to treat degenerative and/or chronic conditions such as osteoarthritis (OA), degenerative disc/spine disease, chronic low back pain, tendinopathy and rotator cuff tears. This includes Arthrex, Emcyte, ISTO Biologics, MiMedx and Harvest/Terumo among others.

The following is a sampling of SmartTRAK market updates covering recently published studies, articles and clinical trials in orthopedic regenerative medicine that were compiled, reviewed and posted in real time by Freddy Buntoum, SmartTRAK’s Sr. Analyst, Regenerative Medicine and Sports Medicine.

Heavy-weight contender ​COVID-19 landed some brutal blows to revenue in Q220, but companies look for better days in the second half of 2020. 

The impact of the COVID-19 crisis started to hit the US Joint Fluid Replacement market late in Q120, and, to some degree, this helped to shield HA companies from heavy punches to revenue. Although none were left KO’d in round one, they still came through bruised up. Going into Q220 for round two, HA companies prepared as best as they could and braced for impact. Unfortunately, COVID-19 is a formidable opponent and even with strong cost-control measures in place, companies were hit hard with huge revenue losses for products in the three largest segments of the US Joint Fluid Replacement market.

Among the many topics covered in the comprehensive Q220 US Joint Fluid Replacement Market Recap* are:

 

Companies came out of the gate strong in Q120, but COVID-19’s one-two punch on elective procedures and capital equipment purchases negatively impacted orthopedic enabling technology revenues toward the end of the quarter.

While adoption of robotics and other enabling technologies was gaining significant momentum quarter over quarter through year-end 2019, delays in elective spine surgery due to the COVID-19 pandemic resulted in declines in capital equipment sales and fewer computer-assisted orthopedic surgeries in Q120.

Among the many topics covered in the comprehensive Q120 CAS Ortho Market Recap* are: